Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00862563 · ClinicalTrials.gov registry record · Phase 2
Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism
A Phase 2 study, sponsored by Boston Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT00862563 is a Phase 2 study that was terminated before completion, run by Boston Medical Center. The registered enrollment target is 85 participants.
The verdict
NCT00862563, a Phase 2 study, was terminated before completion, sponsored by Boston Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
This is a double-blind, placebo-controlled, parallel group design study with 4 treatment groups; levetiracetam, zonisamide, topiramate, and placebo control. Subjects will receive study medications for 14 weeks. Potential subjects will be initially screened for interest in study participation and alcohol consumption level to determine basic eligibility by telephone, or in person. Individuals who meet telephone screening criteria will be scheduled for a clinic appointment to obtain informed consent and conduct screening assessments. Subjects who report average drinks per day that are within the guidelines for safe levels of alcohol consumption (i.e. 2 drinks/ day males; 1 drink/day females-HHS standard) in the two weeks prior to screening will be excluded. Subjects meeting screening criteria will be scheduled for a second randomization visit. During this visit baseline assessments will be obtained. Eligible subjects will then be randomized to a treatment group and will be provided with the first week's study medications. The goal is to directly compare the efficacy and tolerability of two novel anticonvulsants, zonisamide and levetiracetam, with placebo, and using topiramate, which has extensive evidence supporting its efficacy in alcoholism, as a positive control group. We believe that this will be the first direct comparison of these agents in alcoholism, and the results will provide information on the efficacy and safety of the medications.
Interventions
- DRUG Levetiracetam
- DRUG Topiramate
- DRUG Zonisamide
- DRUG Sugar Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2009-05 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00862563
The ClinicalTrials.gov registry entry for NCT00862563 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Levetiracetam is the first listed.
NCT00862563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00862563 about?
NCT00862563 is a clinical study titled "Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism". This is a double-blind, placebo-controlled, parallel group design study with 4 treatment groups; levetiracetam, zonisamide, topiramate, and placebo control. Subjects will receive study medications for 14 weeks. Potential subjects will be initially screened for interest in study participation and alc...
What is the current status of trial NCT00862563?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2009-05. Estimated completion is 2013-08.
What interventions are being tested in trial NCT00862563?
The interventions under investigation include: Levetiracetam (DRUG), Topiramate (DRUG), Zonisamide (DRUG), Sugar Pill (DRUG).
Who is sponsoring clinical trial NCT00862563?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.